Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GGN1231
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**GGN1231** is a novel *losartan-antioxidant hybrid compound* developed for potential therapeutic use in chronic renal failure and related cardiovascular conditions. Preclinical research indicates that GGN1231 combines the angiotensin II receptor antagonism of losartan with an antioxidant moiety, aiming to provide enhanced protective effects against cardiovascular damage, cardiac hypertrophy, and fibrosis in experimental models of chronic renal failure. In rat studies, GGN1231 showed preventive effects on vascular and cardiac damage, with a trend toward reduced mortality, though this reduction was not statistically significant[1][5].
- Other names
- GGN1231GGN-1231GGN 1231
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on GGN1231.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GGN1231.